NCT03558958View on ClinicalTrials.gov

Safety and Efficacy of P-188 NF in DMD Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

August 8, 2018

Primary Completion Date

September 1, 2021

Study Completion Date

September 1, 2021

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

P-188 NF

Poloxamer administered daily via sc injection at 5 mg/Kg

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

Sponsors
All Listed Sponsors
collaborator

Charley's Fund

OTHER

lead

Phrixus Pharmaceuticals, Inc.

INDUSTRY